Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Pulmonary hypertension may be caused by molecular pathway that damages blood vessels

Pulmonary hypertension, a deadly form of high blood pressure that develops in the lungs, may be caused by an inflammation-producing molecular pathway that damages the inner lining of blood vessels, according to a new study by researchers at the Stanford University School of Medicine.

29 Aug 2013

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis.

27 Aug 2013

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.

22 Aug 2013

New drug-delivery strategy for central vision loss

Johns Hopkins biomedical engineers have teamed up with clinicians to create a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur.

20 Aug 2013

Scientists use nanoparticles to regulate DNA interactions in self-assembly, drug-delivery

A team of chemists in SU's Cf ollege oArts and Scientists has used a temperature-sensitive polymer to regulate DNA interactions in both a DNA-mediated assembly system and a DNA-encoded drug-delivery system.

12 Aug 2013

Scientist receives grant to commercialize technology developed for repairing skin injuries

The Chemical Alliance Zone's Chemicals and Materials Commercialization Fund has awarded $20,000 to a Marshall University scientist to help bring to market a technology he has developed for repairing skin injuries.

8 Aug 2013

MedPharm receives new patents for MedSpray topical spray-on-film technology

MedPharm Ltd, the topical drug development specialist, today announced it has been granted a series of further patents for its novel MedSpray topical spray-on-film technology for dermatological, topical and transdermal drug delivery.

6 Aug 2013

BD reports quarterly revenues of $2.053 billion for third fiscal quarter

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for the third fiscal quarter ended June 30, 2013, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 1 Aug 2013

Researchers theoretically create large, hollow magnetic cage molecules that could used in drug delivery system

Virginia Commonwealth University researchers have discovered, in theory, the possibility of creating large, hollow magnetic cage molecules that could one day be used in medicine as a drug delivery system to non-invasively treat tumors, and in other emerging technologies.

1 Aug 2013

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.

30 Jul 2013

Non-invasive optical techniques use LED, laser to view beneath skin

Impressive examples of new non-invasive optical techniques using lasers, light-emitting diodes (LEDs), and spectroscopic methods to probe and render images from beneath the surface of the skin are featured in a newly completed special section in the Journal of Biomedical Optics published by SPIE, the international society for optics and photonics.

26 Jul 2013

Novaliq receives CE mark approval for EyeSol technology

Novaliq GmbH, a drug delivery company with a focus on the topical application of ophthalmic technologies for poorly soluble drugs, today announced the successful CE mark approval for the first topical eye lubricant based on Novaliq's proprietary technology EyeSol.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

22 Jul 2013

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

An investigation undertaken by Novozymes Biopharma DK has shown that when the corticosteroid dexamethasone is formulated in a cross-linked Hyaluronic acid (HA) hydrogel, the drug’s in vitro release time increases from under 10 minutes to approximately 15 hours. In addition, the in vivo half-life of dexamethasone is shown to plateau with stable dexamethasone concentration up to four hours after injection.

22 Jul 2013

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.

20 Jul 2013

Researchers develop new drug delivery technique for diabetes treatment

Researchers have developed a drug delivery technique for diabetes treatment in which a sponge-like material surrounds an insulin core. The sponge expands and contracts in response to blood sugar levels to release insulin as needed. The technique could also be used for targeted drug delivery to cancer cells.

19 Jul 2013

Aquavit Pharmaceuticals signs licensing agreement with U-Bio Med for microneedle technology

Aquavit Pharmaceuticals, Inc. announces it has signed a definitive licensing agreement with U-Bio Med Inc., a medical technology device company in South Korea, for the worldwide commercialization of the company's microneedle device technology.

19 Jul 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.

18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Drug Delivery News and Research

Further Reading

Pulmonary hypertension may be caused by molecular pathway that damages blood vessels

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

New drug-delivery strategy for central vision loss

Scientists use nanoparticles to regulate DNA interactions in self-assembly, drug-delivery

Scientist receives grant to commercialize technology developed for repairing skin injuries

MedPharm receives new patents for MedSpray topical spray-on-film technology

BD reports quarterly revenues of $2.053 billion for third fiscal quarter

Researchers theoretically create large, hollow magnetic cage molecules that could used in drug delivery system

FDA accepts NDA for MNK-795 oral formulation

Non-invasive optical techniques use LED, laser to view beneath skin

Novaliq receives CE mark approval for EyeSol technology

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Researchers develop new drug delivery technique for diabetes treatment

Aquavit Pharmaceuticals signs licensing agreement with U-Bio Med for microneedle technology

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Pharmaron’s drug conjugates platform from idea to XDC eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo